Review of the Chinese Landscape in Phase 1 Clinical Trials for Noncancer Innovative Drugs Over 2015 to 2020-Reference-Cited by-同舟云学术

Review of the Chinese Landscape in Phase 1 Clinical Trials for Noncancer Innovative Drugs Over 2015 to 2020

Published:2022-06-16 Issue:8 Volume:11 Page:903-909
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharm in Drug Dev

Author:

Wu Xiaofei¹,Zhang Fan¹,Yu Mengyang¹,Wang Hongyun¹

Affiliation:

1. Clinical Pharmacology Research Center State Key Laboratory of Complex Severe and Rare Diseases NMPA Key Laboratory for Clinical Research and Evaluation of Drug Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs Peking Union Medical College Hospital Chinese Academy of Medical Sciences & Peking Union Medical College No.1 Shuaifuyuan Beijing 100730 China

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.1131

Reference32 articles.

1. Changes in clinical trials of endocrine disorder and metabolism and nutrition disorder drugs in mainland China over 2010–2019

2. A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Clinical Trial to Assess Safety, Tolerability, and Pharmacokinetics of LY-CovMab, a Potent Human Neutralizing Antibody Against SARS-CoV-2

3. A First-in-Human Trial of GLS4, a Novel Inhibitor of Hepatitis B Virus Capsid Assembly, following Single- and Multiple-Ascending-Oral-Dose Studies with or without Ritonavir in Healthy Adult Volunteers

4. Design and Conduct Considerations for First-in-Human Trials

5. A randomized dose-escalation study on the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of a novel recombinant human albumin in healthy subjects